Literature DB >> 6580171

Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.

T Barbui, S Cortelazzo, P Viero, R Bassan, E Dini, N Semeraro.   

Abstract

A series of 101 consecutive patients with chronic myeloproliferative disorders including polycythaemia vera, chronic myelogenous leukaemia, idiopathic myelofibrosis and essential thrombocythaemia have been studied. The aim was to establish the incidence of thrombotic and haemorrhagic complications and the possible role played by platelet number and function. The total incidence of haemostatic complications was 21% and the platelet functional tests investigated (platelet aggregation, generation of malondialdehyde, endogenous serotonin, beta-thromboglobulin and platelet coagulant activity) were of little help for predicting these clinical complications.

Entities:  

Mesh:

Year:  1983        PMID: 6580171     DOI: 10.1016/0277-5379(83)90091-3

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  7 in total

1.  A Study of Haemostatic Parameters in Patients of Chronic Myeloid Leukaemia.

Authors:  Ankur Jain; Naresh Gupta; Tejinder Singh; Sunita Agarwal
Journal:  J Clin Diagn Res       Date:  2016-07-01

Review 2.  Primary thrombocythemia: diagnosis, clinical manifestations and management.

Authors:  P J van Genderen; J J Michiels
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

Review 3.  What is the standard treatment in essential thrombocythemia.

Authors:  Tiziano Barbui
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

4.  Essential thrombocythaemia as cause of myocardial infarction.

Authors:  A Derks; M H Bloemer
Journal:  Neth Heart J       Date:  2001-12       Impact factor: 2.380

5.  Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms.

Authors:  Loula Papageorgiou; Ismail Elalamy; Patrick Vandreden; Grigoris T Gerotziafas
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

6.  Thrombocythemia and thrombosis of the adrenal vessels.

Authors:  B Barillari; B Shapiro; D Gasparini; M Rocco; A Barillari; S Buzzolo; E Moratti
Journal:  J Endocrinol Invest       Date:  1993-05       Impact factor: 4.256

7.  Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.

Authors:  A Wehmeier; I Daum; H Jamin; W Schneider
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.